Neurexis Therapeutics

About Neurexis Therapeutics

Neurexis Therapeutics is focused on addressing the unmet need for neuroprotective treatments in conditions like stroke and cardiac arrest. The company aims to reduce brain damage and improve quality of life by developing innovative therapies that mitigate the effects of neuronal death and cognitive impairment following ischemic events.

Products & Services

tatCN19o:An optimized peptide with demonstrated efficacy and safety in small and large animal models of global cerebral ischemia, aimed at neuroprotection.

Specialties

Neuroprotective therapies Treatment for stroke and cerebral ischemia

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Direct-to-Phase II SBIR Grant T: - FT: Direct-to-Phase II SBIR Grant	A: 900000 MR: - FA: $900,000 FAN: 900000	D: 2023-04-19 FD: 2023-04-19	1 investors
2	RT: Grant T: - FT: Grant	A: 900000 MR: - FA: $900,000 FAN: 900000	D: 2023-04-19 FD: 2023-04-19	1 investors

Direct-to-Phase II SBIR Grant Latest

2023-04-19

$900K

1 investor (Pro only)

Grant 2023-04-19

$900K

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Michael Artinger

Chief Executive Officer and Board Member

U

Ulli Bayer

Chief Scientific Officer and Board Member

R

Robyn Goforth

Vice President of Research and Development

O

Olivia Asfaha

Chief Operating Officer

N

Nicole Rumian

Senior Scientist

View 2 more team members with Pro

Unlock Full Team Directory

Recent News